Sign in
CC

Crane Co (CR)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 delivered robust top-line and margin expansion: net sales $544.1M (+12.3% YoY), GAAP EPS from continuing operations $1.20 (+61.2% YoY), and adjusted EPS $1.26 (+60.2% YoY). Adjusted operating margin rose 320 bps YoY to 17.7% as price, productivity, and volumes drove leverage .
  • Aerospace & Electronics remained the growth engine (sales +11% YoY; adjusted margin 23.1%, +290 bps), with total aftermarket sales up 21% and record backlog $864M; Process Flow Technologies rose +13% YoY (adjusted margin 20.3%, +330 bps) despite hurricane-related downtime (~$0.09 EPS impact) .
  • Management initiated FY 2025 adjusted EPS guidance of $5.30–$5.60 (12% growth at midpoint), with ~5% total sales growth, adjusted segment margin ≥22.5%, corporate cost ~$80M, net non‑operating expense ~$10M, adjusted tax rate 23.5%, and diluted shares ~59M .
  • Capital deployment optionality increased: dividend raised 12% to $0.23/qtr (annual $0.92), cash $307M vs. debt $247M at year-end, and ~$1.5B of debt capacity for M&A; EM divestiture closed Jan 2, 2025 with ~$208M net proceeds received post quarter .

What Went Well and What Went Wrong

  • What Went Well

    • “Crane Company had an exceptional year… we delivered 8% core sales growth with 28% adjusted EPS growth in 2024” (portfolio sharpened via Vian, CryoWorks, Technifab acquisitions and EM divestiture) .
    • A&E strength: aftermarket +21%, commercial OEM +10%, military aftermarket +36%; adjusted A&E margin 23.1% (+290 bps) and backlog +23% YoY to $864M .
    • PFT margin structurally higher: adjusted margin 20.3% (+330 bps) with “strong core operating leverage… productivity, strong net price and higher volumes” .
  • What Went Wrong

    • Helene hurricane disruption: Marion, NC site downtime at high end of expected headwind (~$0.09 EPS), with recovery underway and insurance expected to offset financial impact .
    • PFT backlog modestly lower sequentially: core FX-neutral backlog −4% YoY on timing of projects, though orders +3% and backlog remains ~40% above 2019 levels .
    • Macro/tariffs: management cited mixed industrial signals; limited concern on China tariff exposure but acknowledged potential 2025 FX headwind (~1 point in sales) embedded in guidance .

Financial Results

MetricQ2 2024Q3 2024Q4 2024
Net Sales ($M)$581.2 $597.2 $544.1
GAAP EPS – Continuing Ops ($)$1.23 $1.33 $1.20
Adjusted EPS ($)$1.30 $1.38 $1.26
Operating Profit Margin (GAAP)16.6% 17.6% 15.8%
Adjusted Operating Margin17.7% 18.3% 17.7%
Adjusted EBITDA Margin19.4% 20.3% 19.8%
YoY Net Sales Growth14.1% 12.7% 12.3%
YoY GAAP EPS Growth65.4% 40.0% 61.2%
YoY Adjusted EPS Growth19.1% 36.1% 60.2%
vs S&P ConsensusN/A (consensus unavailable via S&P Global at time of retrieval)

Segment performance

Segment MetricQ2 2024Q3 2024Q4 2024
A&E Net Sales ($M)$230.9 $239.1 $236.8
A&E Adjusted Operating Margin23.8% 23.5% 23.1%
PFT Net Sales ($M)$297.7 $309.2 $307.3
PFT Adjusted Operating Margin20.5% 21.8% 20.3%

Key KPIs

KPIQ2 2024Q3 2024Q4 2024
Total Backlog ($M)$1,225.8 $1,237.6 $1,240.2
A&E Backlog ($M)$814.9 $833.3 $863.8
PFT Backlog ($M)$399.9 $392.0 $376.4
Cash & Equivalents ($M)$229.3 $258.2 $306.7
Total Debt ($M)$377.0 $332.0 $247.0

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Adjusted EPSFY 2024$5.05–$5.20 (raised/narrowed Oct) Actual $4.88 Not directly comparable; 2024 recast with EM as discontinued ops
Adjusted EPSFY 2025N/A$5.30–$5.60; +12% YoY midpoint Initiated
Total Sales GrowthFY 2025N/A~5% (core +4–6%, acquisitions +1–2%, FX −1%) Initiated
Adjusted Segment Operating MarginFY 2025N/A≥22.5% (vs 21.9% prior year) Raised baseline
Corporate CostFY 2025N/A~$80M Set
Net Non‑Operating ExpenseFY 2025N/A~$10M Set
Adjusted Tax RateFY 2025N/A~23.5% Set
Diluted SharesFY 2025N/A~59M Set
DividendQ1 2025$0.205/qtr (Q4 2024 declared) $0.23/qtr; annual $0.92Raised 12%

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q4 2024)Trend
Supply chain & executionRaised 2024 EPS; noted working capital headwinds; strong backlog Helene impact ~$0.09 EPS; site recovering; 2025 FCF conversion >90% as supply chain improves Improving operational cadence
Tariffs/macroContinued mixed signals; FX modest headwinds in 2024 Mixed industrial signals; limited concern on China tariffs; U.S. stronger; Europe stagnant; China stable Stable-to-improving demand
A&E product/programsBacklog growth; margins expanded (Q2/Q3) Aftermarket +21%; record backlog; F‑16 brake control upgrade orders ~$44M; Boeing ramp embedded Strong demand, multi‑year runway
Cryogenics/semiconductorCryoWorks acquisition benefits (Q2) Technifab added; ~$55M cryogenics revenue; pipeline expansion expected Expanding platform
Regional trendsAmericas/ME/APAC growing; Europe/China weaker (Q3) Same mix; expecting moderate demand improvement in 2025 Gradual improvement
M&A & portfolioBalance sheet optionality; active funnel (Q2/Q3) ~$1.5B debt capacity; diligence on targets in A&E/PFT; EM divestiture closed Active pipeline

Management Commentary

  • “Our initial 2025 adjusted EPS guidance of $5.30–$5.60 reflects what we have confidence in delivering, and reflects solid 12% adjusted EPS growth at the midpoint” .
  • “We generated $234 million of adjusted free cash flow… in 2025, we are confident that we will deliver adjusted free cash flow conversion greater than 90% as the supply chain improves” .
  • “We continue to have substantial financial flexibility with approximately $1.5 billion of debt capacity today for M&A” .
  • “We received the first F‑16 brake control upgrade order… total orders now about $44 million… $150–$200 million life‑of‑program sales including foreign military sales” .

Q&A Highlights

  • PFT backlog dynamics: backlog burn in Q4 reflected execution/timing; orders sequentially consistent; backlog ~40% above 2019; 2025 PFT core growth low-to-mid single digits; margin leverage above the 30–35% norm .
  • Margin trajectory: portfolio mix shift toward higher growth/margin markets continues; line of sight to mid‑20s operating margin at PFT via pricing, innovation, simplification, and operational excellence .
  • A&E cadence: 2025 assumptions—commercial OE low double‑digit, military OE mid‑single-digit, commercial and military aftermarket mid‑ to high‑single-digit; Boeing MAX ramp conservatively embedded .
  • Insurance recovery: business interruption recoveries expected Q2/Q3 2025, offsetting second‑half 2024 income loss; embedded in guidance .
  • Macro/geopolitics: U.S. stronger; Europe stagnant; China stable; limited concern on China tariffs given localization and supply base management .
  • M&A scope: pursuing high‑quality assets in A&E and PFT in the “hundreds of millions” EV range; open to larger transformational opportunities if strategically sound .

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 2024 and forward quarters was unavailable at the time of retrieval due to data access limits; as a result, formal beat/miss analysis versus consensus cannot be provided. Future updates should anchor to S&P Global consensus when accessible.

Key Takeaways for Investors

  • Solid Q4 close with broad-based price/productivity-driven margin expansion and A&E aftermarket/OEM strength; backlog supports sustained growth into 2025 .
  • FY 2025 guide implies continued double-digit EPS growth and higher segment margins, with conservative macro and FX assumptions—setup appears favorable for upside if Boeing/commercial aerospace ramps accelerate .
  • PFT’s structural margin step-up and mix shift provide resilience; watch backlog timing and cryogenics ramp to maintain leverage targets above historical algorithms .
  • Balance sheet optionality and ~$1.5B debt capacity underpin M&A catalysts; recent EM divestiture and dividend hike signal portfolio focus and shareholder returns .
  • Monitor Helene insurance recovery timing (Q2/Q3 2025) and FX headwinds; both are embedded in guidance and could influence intra-year cadence (Q1 seasonally lowest) .
  • Aerospace defense programs (F‑16 brake control, AESA radars) and aftermarket tailwinds provide multi‑year visibility; backlog at record levels de-risks near-term execution .
  • Without consensus data, traders should focus on qualitative catalysts (dividend raise, guidance initiation, backlog/aftermarket strength, M&A pipeline) and upcoming March 6, 2025 A&E Investor Day for incremental signals .